Compass Therapeutics Receives Nasdaq Deficiency Letter After 30 Days Below $1.00
CMPX sits 18% above its 52-week low of $0.57.
Summary
Compass Therapeutics received a Nasdaq notice that its stock has traded below $1.00 for 30 consecutive business days, giving it until May 18, 2027 to regain compliance or potentially face delisting. The company says it may consider a reverse stock split.
Key Events · Legal and Risk Events · CMPX
-
Nasdaq Minimum Bid Price Deficiency
Nasdaq notified Compass on November 19, 2026 that its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days under Listing Rule 5550(a)(2). For now, the stock continues to trade on the Nasdaq Capital Market under CMPX.
-
180-Day Compliance Window to May 18, 2027
Compass has until May 18, 2027 to close at $1.00 or more for a minimum of 10 consecutive business days. At today's $0.6745, the stock needs to roughly double to clear the threshold.
-
Reverse Split Flagged as Fallback
The company said it may consider available options including a reverse stock split. A second 180-day period would require meeting the market value of publicly held shares test and all other initial listing standards, plus notifying Nasdaq of intent to cure.
-
Delisting Risk If Compliance Fails
If Compass does not qualify for or complete a second compliance period, its common stock becomes subject to delisting. An appeal to a Nasdaq Hearings Panel is possible, but there is no assurance of success.
Analysis · CMPX · Life Sciences
The listing itself is not at risk today, but the clock is running: Compass closed below $1.00 for 30 straight business days and now has until May 18, 2027 to get back above the threshold for 10 consecutive days. Its own stated fallback is a reverse stock split, a move that would shrink the share count and reset the price without changing the underlying business. The notice lands seven weeks after the FDA told Compass it needs a new overall-survival trial before it can file for tovecimig in biliary tract cancer, and with the stock at $0.6745 the gap to compliance is roughly a third of the required level. A second 180-day period is possible only if Compass meets the market value of publicly held shares test and all other initial listing standards, and even then a split would likely be required.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMPX was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.9M. The 52-week trading range was $0.57 to $6.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.